Table 1 Clinical characteristics of the children with T. marneffei
Clinical characteristics | Cases (N = 21) |
|---|---|
Demographics | |
Age (months), median (IQR) | 22 (15–34) |
Gender, male (%) | 15 (71.43) |
Endemic area, No(%) | 21 (100.00) |
Month of diagnosis, median (IQR) | 7 (4–9) |
Signs and Symptoms | |
The interval from onset to addmission (days), median (IQR)a | 20 (12–30) |
Fever, No. (%) | 20 (95.24) |
Cough, No. (%) | 17 (80.95) |
Hepatomegaly, No. (%) | 17 (80.95) |
Lymphadenopathy, No. (%) | 15 (71.43) |
Splenomegaly, No. (%) | 12 (57.14) |
Skin lesion, No. (%) | 9 (42.86) |
Dyspnea, No. (%) | 9 (42.86) |
Diarrhea, No. (%) | 6 (28.57) |
Weight loss, No. (%) | 6 (28.57) |
Malnutrition, No. (%) | 4 (19.09) |
Ascites, No. (%) | 1 (4.76) |
Trachyphonia, No. (%) | 1 (4.76) |
Significant complication | |
Sepsis shock, No. (%) | 12 (57.14) |
HLH, No. (%) | 11 (52.38) |
ARDS, No. (%) | 10 (47.62) |
MODS, No. (%) | 9 (42.86) |
DIC, No. (%) | 7 (33.33) |
Specimens for diagnosis | |
Blood, No(%) | 19 (90.48) |
BM, No(%) | 8 (38.10) |
Lymph nodes, No(%) | 4 (19.09) |
Airway mucosal biopsy, No(%) | 2 (9.52) |
BALF, No(%) | 2 (9.52) |
Ascites, No(%) | 1 (4.76) |
Skin, No(%) | 1 (4.76) |
Stool, No(%) | 1 (4.76) |
Antifungal therapy | |
The interval from onset to antifungal therapy (days), median (IQR) | 25 (17.5–31.5) |
Total, No(%) | 19 (90.48) |
Amphotericin B, No(%) | 8 (38.10) |
Voriconazole, No(%) | 8 (38.10) |
Itraconazole, No(%) | 6 (28.57) |
Fluconazole, No(%) | 5 (23.81) |
Caspofungin, No(%) | 3 (14.29) |
Outcomes | |
Length of stay (days), median (IQR) | 14.5 (4–31) |
Mortality, No. (%) | 11 (52.38) |